-
EP4346882
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4346882
| EP4346882 - PHARMACEUTICAL COMBINATION COMPRISING AN ANTI-CD205 ANTIBODY AND AN IMMUNE CHECKPOINT INHIBITOR [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 08.03.2024 Database last updated on 05.05.2025 | |
| Former | The international publication has been made Status updated on 02.12.2022 | ||
| Former | unknown Status updated on 08.06.2022 | Most recent event Tooltip | 02.08.2024 | Change: Validation states | published on 04.09.2024 [2024/36] | Applicant(s) | For all designated states Oxford BioTherapeutics Ltd Suite A, Second Floor The Schrodinger Building Heatley Road Oxford Science Park Oxford OX4 4GE / GB | [2024/15] | Inventor(s) | 01 /
ROHLFF, Christian Abingdon Oxfordshire OX14 4RZ / GB | [2024/15] | Application number, filing date | 22726279.7 | 19.05.2022 | [2024/15] | WO2022GB51256 | Priority number, date | GB20210007518 | 26.05.2021 Original published format: GB 202107518 | GB20210008387 | 11.06.2021 Original published format: GB 202108387 | GB20210009271 | 28.06.2021 Original published format: GB 202109271 | [2024/15] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2022248835 | Date: | 01.12.2022 | Language: | EN | [2022/48] | Type: | A1 Application with search report | No.: | EP4346882 | Date: | 10.04.2024 | Language: | EN | The application published by WIPO in one of the EPO official languages on 01.12.2022 takes the place of the publication of the European patent application. | [2024/15] | Search report(s) | International search report - published on: | EP | 01.12.2022 | Classification | IPC: | A61K39/00, A61K47/68, A61P35/00, C07K16/28, A61P43/00, A61K39/395 | [2024/15] | CPC: |
C07K16/2851 (EP,IL,KR,US);
A61K39/00 (EP,IL,US);
A61K39/395 (EP,IL);
A61K45/06 (KR);
A61K47/68031 (US);
A61K47/68033 (EP,IL,KR,US);
A61K47/68037 (US);
A61K47/6829 (US);
A61K47/6831 (US);
A61K47/6849 (EP,IL,KR);
A61P35/00 (EP,IL,KR,US);
A61P37/04 (US);
A61P43/00 (EP,IL);
C07K16/2809 (US);
C07K16/2818 (EP,IL,KR,US);
C07K16/2827 (EP,IL,KR);
A61K2039/505 (KR);
A61K2039/507 (EP,IL,KR);
| C-Set: |
A61K39/395, A61K2300/00 (EP)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2024/15] | Extension states | BA | 12.12.2023 | ME | 12.12.2023 | Title | German: | PHARMAZEUTISCHE KOMBINATION MIT EINEM ANTI-CD205-ANTIKÖRPER UND EINEM IMMUN-CHECKPOINT-INHIBITOR | [2024/15] | English: | PHARMACEUTICAL COMBINATION COMPRISING AN ANTI-CD205 ANTIBODY AND AN IMMUNE CHECKPOINT INHIBITOR | [2024/15] | French: | COMBINAISON PHARMACEUTIQUE COMPRENANT UN ANTICORPS ANTI-CD205 ET UN INHIBITEUR DE POINT DE CONTRÔLE IMMUNITAIRE | [2024/15] | Entry into regional phase | 12.12.2023 | National basic fee paid | 12.12.2023 | Designation fee(s) paid | 12.12.2023 | Examination fee paid | Examination procedure | 12.12.2023 | Examination requested [2024/15] | 12.12.2023 | Date on which the examining division has become responsible | 20.06.2024 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 28.05.2024 | Renewal fee patent year 03 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [AD]WO2009061996 (CELLDEX THERAPEUTICS INC [US], et al); | [XDY]WO2015052537 (OXFORD BIOTHERAPEUTICS LTD [GB]); | [XY]WO2018162727 (BERLIN CHEMIE AG [DE]); | [Y]US2019023790 (GIURLEO JASON T [US], et al); | [XY]WO2019238843 (BERLIN CHEMIE AG [DE]); | [Y]US2020283536 (CHARATI MANOJ BABURAO [US], et al); | by applicant | US4439196 | US4447233 | US4447224 | US4475196 | US4486194 | US4487603 | US4522811 | US4596556 | US4790824 | US4941880 | US5064413 | US5312335 | WO9413804 | US5374548 | US5383851 | US5399163 | US5399331 | US5416016 | US6214345 | WO02083180 | WO03011161 | WO2004010957 | EP1391213 | WO2004026293 | WO2004043493 | US2005238649 | WO2005112919 | US2006024317 | US2006074008 | WO2006110476 | WO2007018431 | WO2007059404 | WO2007089149 | WO2008104806 | WO2009017394 | US7521541 | WO2009061996 | WO2010062171 | WO2015052537 |